TZDs are specific pharmaceutical ligands for PPARγ, and have been shown to be useful in treating thyroid cancers, through the re-activation of radioiodine-uptake (ClinicalTrials.gov Identifier: NCT00098852) and the promotion of re-differentiation (ClinicalTrials.gov Identifier: NCT01655719) of thyroid cancers [16]. This evidence concerns the gene PPARG and thyroid gland carcinoma.